Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial milestones, R&D spend, and cash-runway figures in Arcutis Biotherapeutics (ARQT) SEC documents can stretch across hundreds of pages. If you need to know how ZORYVE sales offset development costs or where the next PDE4 program stands, wading through every quarterly update is time-consuming and complex.
Stock Titan solves this problem with AI-powered summaries that turn raw disclosures into plain-English takeaways. Whether you are searching for “Arcutis quarterly earnings report 10-Q filing,” want “Arcutis insider trading Form 4 transactions,” or need an “Arcutis proxy statement executive compensation” breakdown, our engine surfaces the exact paragraph in seconds. Real-time alerts appear the moment an “Arcutis Form 4 insider transactions real-time” notice hits EDGAR, while cross-links let you compare each metric historically for quick “Arcutis earnings report filing analysis.”
Dive deeper without the jargon: jump straight to liquidity tables in the “Arcutis annual report 10-K simplified,” scan risk-factor changes, or review pivotal Phase 3 data inside an “Arcutis 8-K material events explained” filing. Many professionals rely on us for “understanding Arcutis SEC documents with AI” because our platform highlights option-exercise patterns under “Arcutis executive stock transactions Form 4,” flags non-recurring charges, and maps clinical timelines to projected market launches. With comprehensive coverage of every 10-K, 10-Q, 8-K, S-1, and Form 4, plus clear explanations, complex immuno-dermatology disclosures finally make sense.
Form 144 filed for Arcutis Biotherapeutics, Inc. (ARQT) discloses a proposed sale of 1,750 common shares through Merrill Lynch on 08/19/2025. The shares were acquired by restricted stock vesting on 08/18/2025. The filer lists four recent sales by Patrick Burnett within the past three months totaling 33,219 shares for aggregate gross proceeds of $521,160.00 (sales on 07/10/2025, 07/14/2025, 08/04/2025, and 08/08/2025). The notice affirms the filer is not aware of undisclosed material adverse information and includes the standard attestation about trading plans and criminal penalties for misstatement.
Polar Capital reports beneficial ownership of 5,006,472 shares of Arcutis Biotherapeutics common stock, representing 4.2% of the class based on 119,201,724 shares outstanding. The filing identifies three reporting persons — Polar Capital Holdings Plc, Polar Capital LLP and Polar Capital Funds PLC - Biotechnology Fund — and classifies their roles as a holding company, an investment adviser and a fund.
All reported shares are held with sole voting and sole dispositive power. The filer certifies the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control. This Schedule 13G/A reflects a passive disclosed stake below the 5% threshold.
Arcutis Biotherapeutics executive Patrick Burnett, the company's Executive Vice President and Chief Medical Officer, sold 3,847 shares of Arcutis common stock on 08/08/2025. The sales were made pursuant to a 10b5-1 trading plan adopted on 12/12/2024 with a plan end date of 02/27/2026. The filing reports a weighted-average sale price of $14.0339, with individual trade prices ranging from $13.992 to $14.12. After the reported transaction, Burnett directly beneficially owned 108,999 shares.
Arcutis Biotherapeutics filed a Form 144 disclosing a proposed sale of 41,979 shares of common stock to be executed through Merrill with an aggregate market value of $611,936. The filing lists the approximate sale date as 08/08/2025 and records total shares outstanding of 119,201,724. The securities were acquired from Arcutis by stock option exercise on 04/10/2024 and are described as shares to be delivered on the stated sale date.
The filing also shows a recent sale in the prior three months: 53,187 shares sold on 08/06/2025 for gross proceeds of $797,466 (seller named as David Topper). The notice includes the standard attestation that the person for whose account the shares will be sold does not possess undisclosed material adverse information about the issuer.
Arcutis Biotherapeutics (ARQT) filed a Form 144 reporting a planned sale of 3,847 common shares to be executed through Merrill Lynch on 08/08/2025. The filing shows these shares were acquired on 08/01/2025 as a restricted stock vest from Arcutis Biotherapeutics, Inc., and lists an aggregate market value of $53,988.51 and the company’s outstanding shares as 119,201,724. The trade is slated for NASDAQ.
The filing also discloses recent sales by Patrick Burnett in the past three months: 23,000 shares on 07/10/2025 for $346,047.00, 5,750 shares on 07/14/2025 for $86,654.00, and 2,622 shares on 08/04/2025 for $37,485.69. No additional commentary or plan-adoption date is provided in the form text.
FAQ
What is the current stock price of Arcutis Biotherapeutics (ARQT)?
What is the market cap of Arcutis Biotherapeutics (ARQT)?
